Olaparib: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1001156/Cv/1'> | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1001156/Cv/1'> | ||
Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting [[poly ADP ribose polymerase]] (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.<ref name="a7">PMID:19553641</ref> See also [https://en.wikipedia.org/wiki/Olaparib Olaparib]. | Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting [[Poly (ADP-ribose) polymerase|poly ADP ribose polymerase]] (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.<ref name="a7">PMID:19553641</ref> See also [https://en.wikipedia.org/wiki/Olaparib Olaparib]. | ||
<scene name='10/1001156/Overall/1'>Poly [ADP-ribose] polymerase 2 in complex with Olaparib</scene> ([[4tvj]]). | <scene name='10/1001156/Overall/1'>Poly [ADP-ribose] polymerase 2 in complex with Olaparib</scene> ([[4tvj]]). | ||